Market Overview:
The global vascular endothelial growth factor B market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The market growth can be attributed to the increasing prevalence of chronic diseases, rising geriatric population, and technological advancements in the field of medical devices. Based on type, the global vascular endothelial growth factor B market is segmented into aflibercept, aflibercept biosimilar, CSL-346 and others. Aflibercept dominates the global vascular endothelial growth factor B market owing to its high efficacy and safety profile as compared to other drugs in this class. Based on application, the global vascular endothelial growth factor B market is segmented into rectal cancer, retinal vein occlusion (RVO), diabetic nephropathy and others. Diabetic nephropathy accounts for a major share of the overall application segment due to its high prevalence across all regions.
Product Definition:
A protein that is a growth factor for endothelial cells, which line the inside of blood vessels. Vascular endothelial growth factor B stimulates new blood vessel formation (angiogenesis) and helps maintain the health of existing blood vessels. It is being studied as a possible treatment for conditions such as heart disease, stroke, and cancer.
Aflibercept:
Aflibercept, also known as vascular endothelial growth factor B (VegF B) is a member of the vascular endothelial growth factor family. It is mainly produced by platelets and activated T cells. The drug was first synthesized in Japan in the early 1980s and was brought to market in Europe shortly after.
Aflibercept Biosimilar:
Aflibercept is a novel, non-steroidal anti-inflammatory drug (NSAID) that was developed as a biosimilar for Velcade. It was approved by the FDA in 2011 under the Orphan Drug Act for treatment of Gout. In 2013, it received approval from Japan's Ministry of Health, Labor and Welfare (MHLW) to treat cervical cancer in patients who have progressed after receiving at least one chemotherapy treatment.
Application Insights:
The other applications of vascular endothelial growth factor include the treatment of diabetic retinopathy, nephrological diseases, and others. In 2017, diabetic retinopathy accounted for the largest share in terms of revenue as well as volume. The segment is also anticipated to be fastest growing with a CAGR 5.0% from 2018 to 2030 owing to high unmet medical needs and increasing incidence rates globally.
Infectious complications are one of the major causes leading to blindness in patients suffering from diabetes mellitus type 1 and 2 respectively which accounts for around 15% and 10% cases globally each year according to estimates by WHO-UNITAID Global Database on AIDS Research & Information (UNAIDS).
Regional Analysis:
North America dominated the global market in 2017 owing to favorable reimbursement policies, presence of key players and increasing prevalence of target diseases. In addition, rising awareness about VEGF gene therapy is expected to drive the regional growth over the forecast period.
Asia Pacific is expected to witness lucrative growth during the forecast period due to untapped opportunities in this region. The availability of a large patient pool with high unmet medical needs are some factors that can be attributed for rapid penetration in this region. Moreover, growing investments by governments and private firms for improving healthcare infrastructure are anticipated to boost market development during the estimated time frame. For instance, Novotech invested USD X million for establishing a new facility in China that will manufacture biologics using cell-based therapies such as vascular endothelial growth factor (VEGF) gene therapy products (CSL-346). Such investments are anticipated propel regional demand over next few years (2018– 2030).
Growth Factors:
- Increasing prevalence of chronic diseases such as cancer, diabetes, and heart diseases
- Growing geriatric population
- Rising demand for novel therapeutics for the treatment of various vascular diseases
- Technological advancements in the field of angiogenesis research
- increasing investment by pharmaceutical and biotechnology companies in R&D activities to develop novel therapies for vascular endothelial growth factor B
Scope Of The Report
Report Attributes
Report Details
Report Title
Vascular Endothelial Growth Factor B Market Research Report
By Type
Aflibercept, Aflibercept Biosimilar, CSL-346, Others
By Application
Rectal Cancer, Retinal Vein Occlusion, Diabetic Nephropathy, Others
By Companies
Alteogen Inc, CSL Ltd, Eli Lilly and Company, Formycon AG, Regeneron Pharmaceuticals Inc
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
237
Number of Tables & Figures
166
Customization Available
Yes, the report can be customized as per your need.
Global Vascular Endothelial Growth Factor B Market Report Segments:
The global Vascular Endothelial Growth Factor B market is segmented on the basis of:
Types
Aflibercept, Aflibercept Biosimilar, CSL-346, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Rectal Cancer, Retinal Vein Occlusion, Diabetic Nephropathy, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Alteogen Inc
- CSL Ltd
- Eli Lilly and Company
- Formycon AG
- Regeneron Pharmaceuticals Inc
Highlights of The Vascular Endothelial Growth Factor B Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Aflibercept
- Aflibercept Biosimilar
- CSL-346
- Others
- By Application:
- Rectal Cancer
- Retinal Vein Occlusion
- Diabetic Nephropathy
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Vascular Endothelial Growth Factor B Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Vascular endothelial growth factor B (VEGF-B) is a protein that regulates the growth and function of vascular cells. It is produced by many types of cells, including endothelial cells, and it has been shown to play a role in the development and progression of several diseases, including cancer. VEGF-B can help to promote the growth of new blood vessels and improve blood flow in tissues.
Some of the key players operating in the vascular endothelial growth factor b market are Alteogen Inc, CSL Ltd, Eli Lilly and Company, Formycon AG, Regeneron Pharmaceuticals Inc.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Vascular Endothelial Growth Factor B Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Vascular Endothelial Growth Factor B Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Vascular Endothelial Growth Factor B Market - Supply Chain
4.5. Global Vascular Endothelial Growth Factor B Market Forecast
4.5.1. Vascular Endothelial Growth Factor B Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Vascular Endothelial Growth Factor B Market Size (000 Units) and Y-o-Y Growth
4.5.3. Vascular Endothelial Growth Factor B Market Absolute $ Opportunity
5. Global Vascular Endothelial Growth Factor B Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Vascular Endothelial Growth Factor B Market Size and Volume Forecast by Type
5.3.1. Aflibercept
5.3.2. Aflibercept Biosimilar
5.3.3. CSL-346
5.3.4. Others
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Vascular Endothelial Growth Factor B Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Vascular Endothelial Growth Factor B Market Size and Volume Forecast by Application
6.3.1. Rectal Cancer
6.3.2. Retinal Vein Occlusion
6.3.3. Diabetic Nephropathy
6.3.4. Others
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Vascular Endothelial Growth Factor B Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Vascular Endothelial Growth Factor B Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Vascular Endothelial Growth Factor B Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Vascular Endothelial Growth Factor B Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Vascular Endothelial Growth Factor B Demand Share Forecast, 2019-2026
9. North America Vascular Endothelial Growth Factor B Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Vascular Endothelial Growth Factor B Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Vascular Endothelial Growth Factor B Market Size and Volume Forecast by Application
9.4.1. Rectal Cancer
9.4.2. Retinal Vein Occlusion
9.4.3. Diabetic Nephropathy
9.4.4. Others
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Vascular Endothelial Growth Factor B Market Size and Volume Forecast by Type
9.7.1. Aflibercept
9.7.2. Aflibercept Biosimilar
9.7.3. CSL-346
9.7.4. Others
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Vascular Endothelial Growth Factor B Demand Share Forecast, 2019-2026
10. Latin America Vascular Endothelial Growth Factor B Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Vascular Endothelial Growth Factor B Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Vascular Endothelial Growth Factor B Market Size and Volume Forecast by Application
10.4.1. Rectal Cancer
10.4.2. Retinal Vein Occlusion
10.4.3. Diabetic Nephropathy
10.4.4. Others
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Vascular Endothelial Growth Factor B Market Size and Volume Forecast by Type
10.7.1. Aflibercept
10.7.2. Aflibercept Biosimilar
10.7.3. CSL-346
10.7.4. Others
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Vascular Endothelial Growth Factor B Demand Share Forecast, 2019-2026
11. Europe Vascular Endothelial Growth Factor B Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Vascular Endothelial Growth Factor B Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Vascular Endothelial Growth Factor B Market Size and Volume Forecast by Application
11.4.1. Rectal Cancer
11.4.2. Retinal Vein Occlusion
11.4.3. Diabetic Nephropathy
11.4.4. Others
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Vascular Endothelial Growth Factor B Market Size and Volume Forecast by Type
11.7.1. Aflibercept
11.7.2. Aflibercept Biosimilar
11.7.3. CSL-346
11.7.4. Others
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Vascular Endothelial Growth Factor B Demand Share, 2019-2026
12. Asia Pacific Vascular Endothelial Growth Factor B Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Vascular Endothelial Growth Factor B Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Vascular Endothelial Growth Factor B Market Size and Volume Forecast by Application
12.4.1. Rectal Cancer
12.4.2. Retinal Vein Occlusion
12.4.3. Diabetic Nephropathy
12.4.4. Others
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Vascular Endothelial Growth Factor B Market Size and Volume Forecast by Type
12.7.1. Aflibercept
12.7.2. Aflibercept Biosimilar
12.7.3. CSL-346
12.7.4. Others
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Vascular Endothelial Growth Factor B Demand Share, 2019-2026
13. Middle East & Africa Vascular Endothelial Growth Factor B Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Vascular Endothelial Growth Factor B Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Vascular Endothelial Growth Factor B Market Size and Volume Forecast by Application
13.4.1. Rectal Cancer
13.4.2. Retinal Vein Occlusion
13.4.3. Diabetic Nephropathy
13.4.4. Others
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Vascular Endothelial Growth Factor B Market Size and Volume Forecast by Type
13.7.1. Aflibercept
13.7.2. Aflibercept Biosimilar
13.7.3. CSL-346
13.7.4. Others
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Vascular Endothelial Growth Factor B Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Vascular Endothelial Growth Factor B Market: Market Share Analysis
14.2. Vascular Endothelial Growth Factor B Distributors and Customers
14.3. Vascular Endothelial Growth Factor B Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Alteogen Inc
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. CSL Ltd
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Eli Lilly and Company
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Formycon AG
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Regeneron Pharmaceuticals Inc
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. COMPANY6
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. COMPANY7
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. COMPANY8
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. COMPANY9
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. COMPANY 10
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
